Baseline clinical characteristics of patients
PD, stage‐IV adenocarcinoma of the lung
MAY
From May 2020 to October 2021, 19 patients were successfully recruited. All patients were diagnosed with stage‐IV adenocarcinoma of the lung by the Department of Pathology of our hospital. The final follow‐up date was June 24, 2022. T790M mutations were found in 11 of the enrolled patients after progression of first‐ or second‐generation EGFR‐TKIs; those 11 patients received osimertinib as their second‐line therapy. Six enrolled patients who were resistant to first‐line treatment with first‐ or second‐generation EGFR‐TKI therapy did not carry the T790M mutation. The remaining two patients were enrolled after PD on first‐line treatment with osimertinib. All patients harbored The median age of this cohort was 61 years. The age range was 41–79 years old. Thirteen (68.4%) patients were female, and 16(84.2%) patients had no previous history of smoking; 14 (73.7%) patients had an ECOG PS score of 0 or 1 (see Table Clinical characteristics of patients.